IVF Immune Protocol: Intralipid, IVIG, Steroids & Antihistamines

An IVF immune protocol is a group of optional add-on treatments — intralipid infusions, IVIG, corticosteroids, G-CSF or antihistamine combinations — given around embryo transfer when immune activity may be interfering with implantation. The evidence is genuinely split: a 2021 meta-analysis of 12 studies found intralipid improved implantation and live birth rates in selected patients, while another systematic review found no measurable impact.

This guide draws on peer-reviewed meta-analyses, randomized controlled trials and clinic-published treatment protocols. It was compiled by the ProIVF Medical Editorial Team and reviewed by the ProIVF Medical Advisory Board.

What Is an IVF Immune Protocol?

An immune protocol is not a single treatment but a family of add-ons prescribed before and after embryo transfer, usually for patients with recurrent implantation failure (RIF) or recurrent pregnancy loss (RPL). The goal is to dampen an overactive immune response that some specialists believe can attack or reject an implanting embryo.

The most common components are:

• Intralipid — a soybean-oil-based intravenous fat emulsion thought to calm natural killer (NK) cells.
• IVIG (intravenous immunoglobulin) — pooled antibodies from thousands of donors, used to modulate the immune response.
• Corticosteroids — prednisone, Medrol (methylprednisolone) or dexamethasone, used to lower inflammation and immune activity.
• G-CSF (Neupogen) — a growth factor used mainly for thin endometrium and some RIF cases.
• Antihistamine protocols — combinations such as intralipid + prednisone + an antihistamine, sometimes with an antibiotic.

None of these are standard IVF care. Most professional societies do not recommend routine use, so adoption usually depends on test results, medical history and the clinic’s own protocol.

How the Immune System May Affect Implantation

The theory centers on natural killer (NK) cells — innate immune cells that normally live in the uterine lining and help remodel blood vessels in early pregnancy. The concern is that abnormally overactive NK cells may mistake an embryo for a threat and interfere with implantation.

Some reproductive immunologists also point to imbalances in T-helper cell ratios (Th1/Th2), thyroid antibodies and antiphospholipid antibodies as immune factors in reproductive failure.

The link between measurable immune markers and IVF outcomes remains contested. The uterus hosts its own NK population (uterine NK, or uNK, cells) that differs from blood NK cells, and no universally accepted test for “abnormal” immune activity exists.

Is Immune Testing Before Treatment Reliable?

Clinics that offer immune protocols usually test first, and the workup typically includes:

• Peripheral blood NK cell activity and counts
• Endometrial (uterine) NK cell biopsy
• Th1/Th2 cytokine ratio
• Antithyroid and antiphospholipid antibodies
• Sometimes HLA typing or cytokine panels

The evidence behind these tests is thin, and patients are usually tested once and then treated on the clinic’s standard protocol. Even specialists who prescribe immune protocols concede the point.

“Abnormal uterine NK cells still need more study as a target to identify patients who may benefit.” — 2021 review of intralipid therapy in assisted reproduction

Intralipid Infusion: The Most Common Add-On

Intralipid is a fat-based IV nutrition solution — 10% soybean oil, 1.2% egg-yolk phospholipids, 2.25% glycerin and water for injection — originally developed for patients who cannot eat. In fertility care it is used as an immune modulator, mainly to lower NK cell activity.

What Does the Evidence Show?

The studies point in different directions, and both sides deserve a hearing.

Two statistical terms help read the numbers: an odds ratio (OR) above 1 means the outcome was more likely in the treated group and below 1 means less likely, while the 95% confidence interval (CI) marks the range in which the true effect most likely sits.

• A 2021 meta-analysis — Kumar et al., Reproductive Fertility — pooled 12 studies with 2,676 participants and linked intralipid to better implantation (OR 2.97, 95% CI 2.05–4.29), clinical pregnancy (OR 1.64, 95% CI 1.31–2.04) and live birth rates (OR 2.36, 95% CI 1.75–3.17), with fewer miscarriages (OR 0.20, 95% CI 0.14–0.30). The authors still stressed intralipid is not routine care — consider it only in patients with normal standard testing, failed standard treatment and immune risk factors.
• A separate 2021 systematic review and meta-analysis — Busnelli et al., Scientific Reports — covered 22 randomized trials and 19 observational studies and found intravenous intralipid showed no impact on IVF outcomes, while subcutaneous G-CSF and intrauterine PBMC infusion looked most promising.
• A 2021 review by Coulam, American Journal of Reproductive Immunology found intralipid improved live births only in RIF or RPL patients with elevated NK cell density on endometrial biopsy — live birth rates of 33–42% in RIF and 75–91% in RPL, and 61% per cycle overall in the treated group.

Intralipid is not a magic bullet, and the research community itself is split. It appears to help a specific subgroup — immune-mediated RIF/RPL with elevated NK activity — but not everyone.

When Is It Given, and Does Timing Matter?

Based on clinic-published protocols — CNY Fertility — and research data, treatment typically begins 1–4 days before the key procedure:

• The first infusion usually runs 1–4 days before IUI, egg retrieval or embryo transfer.
• If pregnancy occurs, infusions may continue weekly through about 12–14 weeks.
• Each session takes roughly 90 minutes to 2 hours.
• A 2025 Japanese comparative study — Hyogo Medical University — found starting immune treatment before transfer produced far higher clinical pregnancy rates than starting on transfer day (IVIG 47.6% vs 0%; lipid emulsion 30.0% vs 12.5%) — timing appears to matter.

Side Effects and Who Should Avoid It

Reported side effects are uncommon and usually mild: headache, temporary fatigue and local irritation at the IV site. Because intralipid contains egg and soy components, it is not recommended for people allergic to either, and — as with any IV therapy — it should be given in a medical setting in case of an infusion reaction.

IVIG: How Is It Different from Intralipid?

IVIG (intravenous immunoglobulin) is made from pooled antibodies from thousands of donors and has decades of use in autoimmune and immunodeficiency disease. In fertility care it targets the same immune indications as intralipid — elevated NK activity, RIF and RPL — and the main practical difference is cost.

Clinics describe intralipid as “far more affordable” than IVIG — CNY Fertility. IVIG needs a larger-volume infusion, often at an infusion center, and a course costs substantially more — which is why many patients choose intralipid when both are offered.

A 2025 comparative study found the two work about equally well in patients with NK cell abnormalities: implantation rates of 48.3% (IVIG) vs 47.8% (intralipid), and live birth rates in RPL patients of 75.0% vs 72.5%, with no significant differences. When immune treatment is indicated, both are reasonable choices, and selection comes down to cost, availability and physician preference.

Steroids in IVF: Prednisone, Medrol and Dexamethasone

Corticosteroids are anti-inflammatory drugs used to suppress immune activity around implantation. Medrol (methylprednisolone) and dexamethasone are typically given for a few days around embryo transfer, while prednisone may run longer.

A 2024 systematic review and meta-analysis of immunosuppressants in RIF — Santos et al., Revista Brasileira de Ginecologia e Obstetrícia — pooled 7 studies with 2,829 patients and found cyclosporine A improved implantation (OR 1.48, 95% CI 1.01–2.18) and clinical pregnancy rates (OR 1.89). Evidence for prednisone itself remains inconsistent, with studies varying in protocol, dose and patient selection.

Steroids are not harmless: long-term or high-dose use can raise blood sugar, swing mood, cause insomnia and increase infection risk. Short courses around transfer are generally well tolerated, but the decision should be weighed against evidence that is weaker than most patients realize.

G-CSF, or Neupogen: Thin Endometrium and RIF

G-CSF (granulocyte colony-stimulating factor) is a growth factor that stimulates white blood cell production, used in fertility care for two purposes: improving thin or refractory endometrium and, in some clinics, treating RIF.

In the Busnelli 2021 meta-analysis, subcutaneous G-CSF was one of the two most promising RIF interventions, with a clinical pregnancy rate ratio of 2.29 (95% CI 1.58–3.31) — treated patients conceived at roughly 2.3 times the control rate. It is given as a subcutaneous injection, sometimes as an intrauterine infusion, and dosing varies widely between clinics.

G-CSF is generally considered low-risk, with mild bone pain, fatigue and injection-site reactions being the common side effects. Like other immune add-ons, it is not standard treatment and should be discussed with a specialist experienced in RIF.

The Antihistamine Protocol

The “antihistamine protocol” is a combination regimen popularized by some fertility clinics — usually intralipid + prednisone + an antihistamine such as loratadine or cetirizine, sometimes with an antibiotic and low-dose aspirin — designed to cover several immune and inflammatory pathways at once.

No randomized trial has validated the combination itself. Its use rests on the separate evidence for its components (intralipid, steroids) plus clinical experience, so patients should treat it as an off-label, evidence-light mix whose exact contents differ substantially from clinic to clinic.

Immune Add-Ons at a Glance

Read across the table, the pattern is consistent: the benefit signal concentrates in narrow, immune-defined subgroups. Outside those subgroups the evidence is weak and every option stays optional.

Who Should Consider an Immune Protocol?

Most clinics reserve immune protocols for patients with a documented pattern of immune-linked failure:

• Two or more miscarriages (recurrent pregnancy loss)
• Multiple failed transfers with good-quality embryos (recurrent implantation failure)
• Elevated NK cell activity on testing
• A known autoimmune condition or immune-related fertility concerns
• A history of chemical pregnancies or repeated early losses

After a single failed transfer, an immune protocol is rarely the first step — standard evaluation of the uterine cavity, embryos and hormonal environment comes first. The recurrent implantation failure guide walks through that full workup, and the recurrent pregnancy loss guide covers the miscarriage pathway.

What Did Two Patients Experience?

Both stories are shared with consent; names and identifying details have been changed to protect privacy.

Case 1: RIF at 36 — Bangkok, Thailand. After two failed transfers of high-grade blastocysts, “Lin” asked her doctor why good embryos were not implanting. The clinic ran an NK cell panel and a hysteroscopy; nothing structural appeared, but her blood NK cell activity came back above the clinic’s threshold. Her third cycle added intralipid infusions starting four days before transfer, then weekly — “the easiest part of the whole cycle, an hour and a half with my phone,” she said.

She got a positive pregnancy test after that transfer and continued infusions through week 10. The immune add-ons were self-pay and added roughly $1,500–2,000 to the cycle, which she had not budgeted for.

Case 2: Two miscarriages at 40 — California, USA. “Elena” had two early losses from IVF transfers and was told by one clinic it was likely just egg quality. Before her next frozen transfer she sought a second opinion and was tested for thyroid antibodies, antiphospholipid antibodies and NK cells. Her doctor recommended a short prednisone course from five days before transfer, plus intralipid — “what convinced me was that they explained exactly what each drug was for, and what the evidence was, and wasn’t.”

That cycle ended in a chemical pregnancy and the next in a clinical pregnancy. Her financial note is blunt: each intralipid infusion cost a few hundred dollars out of pocket, the steroids were cheap, and the uncertainty cost the most.

Both cases show the same pattern: immune protocols get added only after standard evaluations come back normal, they are self-pay, and the emotional and financial cost of uncertainty is real. Individual results vary, and these stories do not predict your outcome.

Why Is the Evidence Still Controversial?

Immune protocols are among the most controversial add-ons in reproductive medicine, and four problems explain why.

• Conflicting meta-analyses. One meta-analysis supports intralipid in selected patients; another found no impact. The question is unresolved.
• Unvalidated testing. NK cell assays are not standardized, and abnormal uterine NK cells still “need more study as a target” — even advocates admit testing lags behind treatment.
• Financial burden. These treatments are usually self-pay, rarely insured, and can add hundreds to thousands of dollars per cycle.
• Over-treatment risk. Some clinics market immune protocols to patients who do not meet evidence-based criteria — ask exactly what testing was done and what the clinic’s own success data shows.

Bottom line: for a small, immune-defined subgroup — RIF/RPL with elevated NK activity — there is reasonable evidence that intralipid (or IVIG) may help. For everyone else, the evidence is weak and the treatments are optional.

FAQ

Q: Is intralipid safe during IVF?

A: In fertility use, side effects are uncommon and usually mild — headache, temporary fatigue and IV-site irritation — and each infusion takes 90 minutes to 2 hours. Because it contains egg and soy, it is not recommended for people with allergies to either; tell staff immediately if you develop a rash, fever or breathing difficulty during an infusion.

Q: How much does an intralipid infusion cost?

A: CNY Fertility describes intralipid as “far more affordable” than IVIG, making it one of the cheaper immune add-ons, while IVIG courses typically run into thousands of dollars. A complete intralipid-based add-on course ran $1,500–$2,000 out of pocket for one Bangkok patient in this guide — published prices vary and are rarely listed online, so ask for an itemized quote and confirm whether repeat infusions are included.

Q: Do immune protocols increase IVF success rates?

A: The data is split. A 2021 meta-analysis reported better implantation (OR 2.97) and live birth (OR 2.36) rates in selected patients with recurrent failure, while another systematic review found no effect from intravenous intralipid.

The clearest benefit signal is in patients whose endometrial biopsy shows elevated NK cell density (Coulam 2021).

Q: When should intralipid start before transfer?

A: Most clinic protocols begin 1–4 days before egg retrieval or embryo transfer, then repeat weekly to about 12–14 weeks of pregnancy. A 2025 Japanese study found pre-transfer starts produced far higher clinical pregnancy rates than transfer-day starts (IVIG 47.6% vs 0%; intralipid 30.0% vs 12.5%).

Q: What is the difference between intralipid and IVIG?

A: Both are intravenous immune modulators used for similar indications — intralipid is a soybean-oil fat emulsion, IVIG is pooled donor antibodies. A 2025 comparison found near-identical implantation (48.3% vs 47.8%) and RPL live birth rates (75.0% vs 72.5%), so cost (intralipid is far cheaper), availability and physician preference decide.

Q: Is NK cell testing reliable?

A: Not fully. No standardized, universally accepted test for abnormal NK activity exists, uterine NK cells are hard to measure consistently, and most clinics test just 1 time before prescribing a standard protocol.

Interpret any result with a clinician experienced in reproductive immunology rather than deciding on a single reading.

Q: Does insurance cover IVF immune protocols?

A: Almost never. Intralipid, IVIG, steroids and G-CSF for fertility purposes are treated as add-on or investigational treatments and are typically self-pay, adding hundreds to thousands of dollars per cycle — one patient in this guide paid $1,500–$2,000 for her full intralipid course.

Budget the entire course, including repeat infusions, before committing.

Q: Are immune protocols safe during pregnancy?

A: Intralipid and IVIG are generally considered low-risk in pregnancy when medically indicated, and some protocols continue weekly infusions through 12–14 weeks. Corticosteroids need closer monitoring, especially over longer courses — confirm any plan with the clinic’s medical team and your obstetrician.

How to Plan Your IVF Journey

If you are considering an immune protocol, complete the standard workup first — uterine, embryonic and hormonal causes of failure — as explained in the recurrent implantation failure guide and the recurrent pregnancy loss guide.

When evaluating clinics, ask three questions: what immune testing do you run, what protocol would you use for my history, and what are your own success rates for patients like me. The how to choose an IVF clinic guide shows how to compare clinics fairly, and you can browse verified providers in the ProIVF hospital directory, including fertility clinics in Thailand that frequently offer immune-related care.

Get an itemized quote before starting: immune add-ons are almost always self-pay, and a full intralipid course through 12–14 weeks of pregnancy adds real cost on top of the IVF cycle itself.

Written by the ProIVF Medical Editorial Team and reviewed by the ProIVF Medical Advisory Board, this article is based on peer-reviewed studies (Kumar et al. 2021; Busnelli et al. 2021; Coulam 2021; Santos et al. 2024; Yamaya et al. 2025) and clinic-published treatment information (CNY Fertility). Protocol and cost details cited here come from public clinic disclosures, and ProIVF has no commercial relationship with any clinic mentioned.

This article is for educational purposes only and is not medical advice. Always discuss treatment decisions with a licensed fertility specialist. Last updated: August 24, 2026.